UKPDS 34
1998
UK Prospective Diabetes Study 34
In 753 overweight patients with newly diagnosed type 2 diabetes, intensive control with metformin reduced diabetes-related endpoints and all-cause mortality compared with conventional therapy.
Result
Primary endpoint: Any diabetes-related endpoint
Any diabetes endpoint −32 % (p=0.002); all-cause mortality −36 % (p=0.011); MI −39 % (p=0.01).
- Subtopic
- Metformin
- Design
- RCT, median 10.7 yr follow-up
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- UKPDS Group. Lancet. 1998;352(9131):854-865.doi 10.1016/S0140-6736(98)07037-8
Discussion & critique
Established metformin as first-line therapy in overweight T2DM, a position it still holds.